Europe At the recent FT webinar, ‘Supporting Pharma Innovation in Europe’, high-level representatives from Roche, Bayer, and the European Commission weighed in on how European pharma’s competitive position on innovation is being challenged and the policy measures that need to be enacted to solve this issue. Read on for five key…
Spain While Spain’s scientific infrastructure has long been hailed as world-class, the southern European nation has often struggled to translate its excellent science into viable commercial companies. However, a growing cadre of clinical-stage firms are aiming to change that narrative and become the biotech success story that Spain so desperately craves.…
Europe Writing in the December edition of DIA’s Global Forum magazine, Thomas Kühler updates his August piece on the progress towards a unified HTA system in Europe and the objectives of the recently launched EUnetHTA 21 initiative. Global Forum recently published a piece on Health Technology Assessment (HTA) in the EU and how a regulation…
Denmark Europe lags behind the US in terms of biotech success stories, but one company bucking that trend is Denmark-headquartered Genmab, with a market cap of over USD 25 billion. Dual-listed on the Copenhagen stock exchange and on NASDAQ in the US, there are five products based on Genmab science on…
Spain A rundown of five things to know about the healthcare and life sciences industry in Catalonia. Nestled in Northeastern Spain and bordering France, Catalonia’s capital and largest city is Barcelona. The region boasts a strong scientific output by European standards, is the birthplace of many of Spain’s pharma success stories,…
Denmark Speaking exclusively to PharmaBoardroom, Jan van de Winkel highlights the tremendous progress that European biotech success story Genmab has made over the past six years, how its partnership model is evolving, Denmark’s continuing relevance to the company, and Genmab’s value proposition for the next generation of talent. Genmab has…
Denmark Although Zealand Pharma has been around for 23 years, it has made rapid progress since French national Emmanuel Dulac took the helm as president and CEO in April 2019, with a first new drug application (NDA) and approval, a first in-licensing, and two acquisitions. Dulac – a veteran of…
France The latest news from French pharma, including AI-based biotech Owkin’s new status as a USD one billion-valued unicorn following fresh investment from Sanofi. Also included is another deal for Sanofi, this time in the form of a partnership with Chinese tech giant Baidu to use its algorithm for mRNA sequencing.…
Europe Building on points developed in his 2020 PharmaBoardroom interview, Professor Nicolaus Kröger of the European Society for Blood and Marrow Transplantation (EBMT) outlines the progress made by the multi-stakeholder GoCART Coalition towards greater harmonisation of cell and gene therapy research in Europe, the challenges of integrating patient-reported outcomes into its…
Europe In the wake of the 2021 United Nations Climate Change Conference (COP26), sustainability is once more a hot-button issue across all industries, including pharma. Here, Marco Rauland, vice president global market access & pricing strategic planning at Merck Group, casts his eye across Europe to assess how sustainability criteria are…
Denmark The BioInnovation Institute (BII) is an initiative from the Novo Nordisk Foundation which aims to support entrepreneurial researchers and early-stage life science start-ups with up to DKK 18 million in founder-friendly funding. CEO Jens Nielsen highlights some of the BII’s milestones and success stories since its formation and Denmark’s progress…
Europe Cyril Titeux, senior VP mid-sized markets EMEA & strategic leader at Janssen, argues that the current focus of many health systems on efficiency, streamlining, and reducing spending is leaving them ill-prepared to absorb the shock of future crises. Titeux instead posits the need for the building up of resilience and…
See our Cookie Privacy Policy Here